Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Dilaforette is Granted SEK 2.85m from Vinnova

Published: Tuesday, November 06, 2012
Last Updated: Monday, November 05, 2012
Bookmark and Share
Development of sevuparin for the treatment of severe malaria.

Dilaforette has announced that it has been granted SEK 2.85m from the Swedish Governmental Agency for Innovation Systems, Vinnova, for the development of sevuparin, a new potential treatment for severe malaria.

Sevuparin is intended as an adjunctive therapy to anti-parasite medicines in order to prevent the infected red blood cells from obstructing blood vessels and thereby reducing mortality.

Each year nearly 10 million people are diagnosed with severe malaria and about one million die of the disease.

The grant from Vinnova will be used for process and method development and validation. The project is in Phase II with a clinical study ongoing in Thailand in collaboration with leading malaria clinicians at the Mahidol Oxford Tropical Medicine Research Unit, which is supported by the Wellcome Trust.

“We are very pleased that sevuparin was selected by Vinnova, in high competition. The additional funding will take sevuparin one step further towards a treatment of severe malaria, a disease where more efficacious medications are urgently needed”, says Pirkko Sulila Tamsen, CEO of Dilaforette.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Dilaforette Receives Positive COMP Opinion
Positive opinion on orphan drug designation in the EU for sevuparin in sickle-cell disease.
Thursday, January 22, 2015
Dilaforette Presents Results from Exploratory Phase I/II Clinical Trial in Uncomplicated Malaria
Aim of the trial was to study sevuparin in adult patients with uncomplicated falciparum malaria.
Saturday, May 31, 2014
Scientific News
Therapy Halts Progression of Lou Gehrig’s Disease
Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
UTSW Researchers Identifies How Drugs Alter Pancreatic Cancer Cells
The findings were published in Cell Reports.
Researchers Identify Process that Causes Chronic Neonatal Lung Disease
Study determines how the NLRP3 inflammasome activates the protein Interleukin 1 beta.
Dengue Vaccine Enters Phase 3 Trial
Investigational vaccine to prevent ‘breakbone fever’ developed at NIH.
Trying to Conceive Soon After a Pregnancy Loss May Increase Chances of Live Birth
NIH study finds no reason for delaying pregnancy attempts after a loss without complications.
BRCA1 Deficiency Increases the Sensitivity of Ovarian Cancer Cells to Auranofin
An anti-rheumatic drug could improve the prognosis for ovarian cancer patients exhibiting a deficiency of the DNA repair protein BRCA1, a study suggests.
Shingles Vaccine Helps Protect Older Patients with End-stage Renal Disease
Kaiser Permanente study advances knowledge about safety and effectiveness of vaccine commonly given to older adults.
AMRI Acquires Whitehouse Laboratories
Strategically extends AMRI's analytical offerings in rapidly expanding area of outsourcing services.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!